Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance
활용도 Analysis
논문 Analysis
연구자 Analysis
'
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance' 의 참고문헌
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors
Use of poly ADP-ribose polymerase [PARP]inhibitors in cancer cells bearing DDR defects : the rationale for their inclusion in the clinic
Upregulation of poly(ADP-ribose)polymerase-1(PARP1)in triple-negative breast cancer and other primary human tumor types
Trapping of PARP1 and PARP2 by clinical PARP inhibitors
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
The kinase polypharmacology landscape of clinical PARP inhibitors
The involvement of poly(ADP-ribose)polymerase in the degradation of NAD caused by gamma-radiation and N-methyl-N-nitrosourea
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Structure of the catalytic fragment of poly(AD-ribose)polymerase from chicken
Structural basis for potency and promiscuity in poly(ADPribose)polymerase(PARP)and tankyrase inhibitors
Structural basis for allosteric PARP-1 retention on DNA breaks
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase
Specific binding of snoRNAs to PARP-1promotes NAD(+)-dependent catalytic activation
Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality
Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor Rucaparib in high-grade ovarian carcinoma
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma(ARIEL2 Part 1) : an international, multicentre, open-label, phase 2 trial
Role of poly(ADP-ribose) formation in DNA repair
Restoration of replication fork stability in BRCA1- and BRCA2-deficient cells by inactivation of SNF2-family fork remodelers
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
Resistance to therapy caused by intragenic deletion in BRCA2
Rescue of arrested replication forks by homologous recombination
Replication fork stability confers chemoresistance in BRCA-deficient cells
Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets
Poly(ADPribose) polymerase auto-modification and interaction with DNA: electron microscopic visualization
Poly(ADP-ribosylation) in vitro. Reaction parameters and enzyme mechanism
Poly(ADP-ribosyl)ation by PARP-1 : ‘PARlaying’ NAD+ into a nuclear signal
Poly(ADP-ribose)polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
Platinum and PARP inhibitor resistance due to overexpression of microRNA-622 in BRCA1-mutant ovarian cancer
Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose)polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2mutations and recurrent ovarian cancer
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies
Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
PARPs and ADP-ribosylation in RNA biology : from RNA expression and processing to protein translation and proteostasis
PARP trapping beyond homologous recombination and platinum sensitivity in cancers
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
PARP inhibitors: clinical utility and possibilities of overcoming resistance
PARP inhibitors in gynecologic cancers: what is the next big development?
PARP inhibitors : synthetic lethality in the clinic
PARP inhibitors : extending benefit beyond BRCA-mutant cancers
PARP inhibitor treatment in ovarian and breast cancer
PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells
PARP and PARG inhibitors in cancer treatment
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
Olaparib maintenance therapy in patients with platinumsensitive relapsed serous ovarian cancer : a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer
Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme
Modulation of chromatin superstructure induced by poly(ADP-ribose)synthesis and degradation
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments
Mechanism for synthetic lethality in BRCA-deficient cancers : no longer lagging behind
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors
Laying a trap to kill cancer cells:PARP inhibitors and their mechanisms of action
Inhibition of poly(ADP-ribose)polymerase in tumors from BRCA mutation carriers
Homology-directed repair and the role of BRCA1, BRCA2, and related proteins in genome integrity and cancer
High speed of fork progression induces DNA replication stress and genomic instability
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
Does the ribosome translate cancer?
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
Characterization of polymers of adenosine diphosphate ribose generated in vitro and in vivo
Characterization of poly(ADP-ribose)-histone H1 complex formation in purified polynucleosomes and chromatin
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
Blocking c-Met-mediated PARP1 phosphorylation enhances antitumor effects of PARP inhibitors
BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance
Adenosine diphosphate ribosylation of histone H1 by purified calf thymus polyadenosine diphosphate ribose polymerase
Activation of PARP-1 by snoRNAs controls ribosome biogenesis and cell growth via the RNA helicase DDX21
Ablation of PARP-1does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks
A targeting modality for destruction of RNA polymerase I that possesses anticancer activity
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks
'
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance'
의 유사주제(
) 논문